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Abstract
Background: Fluid resuscitation in massive bleeding may cause coagulation disorders by dilution of 
platelets and clotting factors or by the impact on their function. The aim of this study was to investigate 
the effects of balanced crystalloid and colloid solutions on platelets in vitro using complex assessment 
of coagulation.
Methods: The study group was comprised of 32 American Society of Anesthesiologists physical status 
class I male volunteers, aged 21–35 (29 ± 4) years, weighting 59–103 (81.2 ± 9.8) kg. Whole blood 
samples were diluted at a 4:1 ratio with the following fluids: balanced crystalloid (Plasmalyte®), 6% 
hydroxyethyl starch 130/0.4 (Volulyte®) and succinylated gelatin (Geloplasma®). Coagulation was as-
sessed using standard morphology, rotational thromboelastometry and aggregometry. 
Results: Dilution with all fluids caused statistically significant drop in the number of platelets (p < 0.01)  
but the effect did not differ between solutions (p > 0.05 for all). Other platelet parameters, such as 
platelet distribution width, mean platelet volume and platelet-large cell ratio were not affected by the 
solutions. Hemodilution had no effect on platelet function (p = 0.1). Decreased platelet component of clot 
strength was found for all three fluids (p < 0.05), although the effect for colloids was more pronounced. 
Conclusions: The effect of balanced crystalloids and colloids on platelet aggregation was insignificant, 
even after 20% volume substitution with the resuscitation fluids. (Cardiol J 2018; 25, 2: 254–259)
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Introduction
Prudent management of bleeding subjects 
or those non-bleeding but who are at high risk of 
hemorrhage is becoming more challenging.
Massive bleeding is considered generally as 
the loss of one blood volume within a 24 h period 
or a 50% blood volume within 3 h, or a rate of loss 
of 150 mL/min. It is a life-threatening condition 
encountered in many surgical disciplines [1] and 
in major trauma where it is the primary cause of 
death in up to one third of patients [2].
According to the current guidelines [3, 4], 
intravascular volume therapy is the first line treat-
ment during massive bleeding. Crystalloids and 
colloids are essential to restore cardiac output and 
improve tissue oxygenation in patients with hemor-
rhagic shock. Simultaneously, both expanders may 
cause or exaggerate bleeding diathesis. Depending 
on their constituents and/or carrier solution, they 
may impair blood coagulation in different ways. The 
effects may be mediated by dilution of platelets 
and clotting factors or by the specific influence on 
their function [5].
The aim herein was to investigate the effects 
of frequently used balanced crystalloid and colloid 
solutions on platelets in vitro by means of a com-
plex assessment of coagulation.
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Methods
The study was approved by the Bioethics 
Committee of the Medical University of Silesia in 
Katowice (KNW/0022/KB1/158/15/16). Written 
informed consent was obtained from 32 American 
Society of Anesthesiologists (ASA) physical status 
class I male volunteers, aged 21–35 (29 ± 4) years, 
weighting 59–103 (81.2 ± 9.8) kg, with no previous 
history of coagulopathy. No drugs were allowed 
for 1 week and no alcohol or strenuous physical 
exercise for 1 day prior to blood sampling. 
Sampling
Venous blood samples were drawn via a 16 G or 
18 G indwelling cannula from an antecubital vein of 
a non-dominant arm. Only minimal stasis was allowed 
to reduce the risk of pre-analytical error [6]. The first 
portion of blood (2 mL) was discarded and four blood 
samples were drawn:  baseline (BL, 12.5 mL) and one 
blood sample (10 mL) for every study fluid. Samples 
were collected in citrated blood tubes (S-Monovette, 
Sarstedt, Germany) for complete blood count (CBC) 
and rotational thromboelastometry analysis, and 
hirudin blood tubes (S-Monovette, Sarstedt, Ger-
many) for platelet aggregometry. Hirudin test tubes 
were used because alternative anticoagulants have 
been shown to affect the results of multiple electrode 
aggregometry (MEA) [7]. Immediately following 
collection, samples were processed using rotational 
thromboelastometry or sent to the central hospital 
laboratory for analysis. Samples were delivered to 
the laboratory in person because pneumatic tube 
transport systems have been shown to affect deter-
minations made with MEA [8, 9].
Hemodilution
The study solutions included balanced crystal-
loid (Plasmalyte®, Baxter) (PL), 6% hydroxyethyl 
starch 130/0.4 (Volulyte®, Fresenius Kabi) (VL) 
and succinylated gelatin (Geloplasma®, Fresenius 
Kabi) (GEL). Whole blood samples were diluted 
with study solutions at a 4:1 ratio to make an 
end-concentration of 20 vol.% for each solution, 
equivalent to an infusion of about 1 L into a 70 kg 
person. Taking into account mean weight of volun-
teers (81.2 ± 9.8 kg), the average amount of study 
solution administered in this recreated scenario 
was 15 mL/kg. The investigator performing dilu-
tions was not blinded to study solutions used.
Thromboelastometry
Rotational thromboelastometry analysis was car-
ried out using a four-channel ROTEM® delta analyzer 
(Tem Innovations GmbH, Germany), ROTEM-based 
assays were allowed to run for 30 min. To minimize 
a pre-analytical error samples were analyzed imme-
diately after collection. The following whole blood 
ROTEM assays were performed: INTEM, EXTEM 
and FIBTEM. The INTEM (describing intrinsic co-
agulation pathway) uses phospholipid and ellagic acid 
as activators. The EXTEM is an extrinsic coagula-
tion assay initiated by the addition of a tissue factor. 
The FIBTEM assay measures effect of fibrin on clot 
firmness and uses cytochalasin D to inhibit plate-
lets. In both former assays we measured maximum 
clot firmness (MCF), i.e. parameter influenced by 
platelets, fibrin and factor XIII. The MCF value was 
used  to calculate maximum clot elasticity (MCE) for 
both assays using the formula MCE = 100 × MCF/ 
/100 – MCF. Assessment of platelet contribution to 
clot strength was measured according to formula 
DMCE = MCEEXTEM – MCEFIBTEM.
Aggregometry
MEA was applied using Multiplate analyzer 
(Roche Diagnostics GmbH, Germany), along with 
the thrombin receptor activating peptide-6 (TRAP-6) 
as a platelet activator. Aggregation units (AU) were 
calculated. The reference values provided by the 
laboratory were 941–1563 AU*min. 
Standard tests
Standard laboratory test (SLT) of coagulation in-
cluded CBC with assessment of platelets (reference 
value 150000–450000/µL) and allied parameters, e.g. 
platelet distribution width (PDW), mean platelet 
volume (MPV) and platelet-large cell ratio (P-LCR).
Statistical analysis
The statistical analysis was performed us-
ing the licensed MedCalc software (version 16.1 
2016, MedCalc Software bvba, Belgium). The 
quantitative variables are presented as a median 
(interquartile range [IQR]) or a mean (± standard 
deviation). The type of distribution was verified 
using Shapiro-Wilk test. The differences between 
results obtained for particular study solutions 
were analyzed using repeated measures of ANOVA 
or Friedman test. Post-hoc comparisons were 
performed using the Scheffe test or the Conover 
post-hoc analysis, when appropriate. The level of 
statistical significance was set at p < 0.05.
Results 
Dilution with all study solutions caused a sta-
tistically significant drop in the number of platelets 
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(p < 0.01) but the effect did not differ between 
solutions (p > 0.05 for all) (Fig. 1). 
The effect of study solution on degree of 
hemodilution is depicted in Figure 2.
Following administration of PL, VL and GEL 
blood platelet counts dropped by 21.6%, 19.8% and 
25.5%, respectively. Other platelet parameters, 
such PDW, MPV and P-LCR were not affected by 
the solutions (Figs. 3–5). 
Hemodilution had no effect on platelet function 
as evidenced by MEA (p = 0.1) (Fig. 6). The plate-
let contribution to clot strength, as determined by 
DMCE, is shown in Figure 7. Decreased platelet 
component of clot strength was found for all three 
fluids (p < 0.05), although the effect for colloids 
was more pronounced. Platelet component of clot 
strength decreased to 83.2%, 78.1%, 77.4% for PL, 
VL and GEL, respectively. 
Figure 1. Effect of study solutions on platelet (PLT) count; 
BL — baseline; PL — Plasmalyte®; VL — Volulyte®; 
GEL — Geloplasma®.
Figure 2. Effect of study solution on hematocrit; 
BL — baseline; PL — Plasmalyte®; VL — Volulyte®; 
GEL — Geloplasma®.
Figure 3. Effect of study solutions on platelet distribu-
tion width (PDW); BL — baseline; PL — Plasmalyte®; 
VL — Volulyte®; GEL — Geloplasma®.
Figure 4. Effect of study solutions on mean platelet volume 
(MPV); BL — baseline; PL — Plasmalyte®; VL — Volulyte®; 
GEL — Geloplasma®.
Figure 5. Effect of study solutions on platelet-large 
cell ratio (P-LCR); BL — baseline; PL — Plasmalyte®; 
VL — Volulyte®; GEL — Geloplasma®.
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of number of platelets) remained within reference 
laboratory values.
These results are in line with previous inves-
tigations showing that crystalloids have less effect 
on blood coagulation compared to colloids [10]. Con-
trary to a few other studies, we revealed that platelet 
function was not affected by the study solutions. 
Williams et al. [5] found that platelet function 
was impaired only at high levels of hemodilution 
(40% dilution with 6% hydroxyethyl starch [HES] 
130/0.4 and 0.9% NaCl), as evidenced by light 
transmission aggregometry (LTA) or MEA. Minor 
or moderate hemodilution have shown no effect on 
platelet function. Both fluids examined in this study 
affected platelet function to a similar, insignificant 
degree. This discrepancy may be explained by the 
fact that MEA results were interfered with platelet 
counts were lower than 150000/µL [11], although 
large variations have been observed between indi-
viduals and normal values of MEA were reported 
for platelet counts as low as 50000/µL [12].
Treib et al. [13] noticed decreased MPV follow-
ing HES administration, this effect was seen after 
several days of its administration. This study did 
not observe a similar effect, probably due to short 
exposure to HES.
Liu et al. [14] showed that HES 200/0.5 and 
130/0.4 inhibited platelet aggregation ex vivo 
and the effect was more noticeable with dilu-
tions higher than 20%, and for HES with higher 
molecular weight. Shaden et al. [15] showed that 
only saline-based HES 130/0.42 solutions, but not 
balanced solution-based HES, administered at 
a dose of 20 mL/kg, significantly decreased platelet 
aggregation in response to adenosine diphosphate 
(ADP) in healthy volunteers.
In a recent study Li et al. [16] showed no 
changes in Multiplate results (ADP-test, TRAP-
test) following infusion of up to 1000 mL of HES 
130/0.42 in neurosurgical patients.
Evans et al. [17] investigated the impact of two 
different gelatin-based fluids on platelet function 
in vitro. The authors added fluids to make an end-
concentration of 40%. Both solutions prevented 
platelet aggregation induced by ristocetin, although 
platelet inhibition was more pronounced after 
Haemaccel®, probably due to high Ca+2 content. 
Haemaccel® also inhibited aggregation induced 
by other activating factors, namely ADP, platelet 
activating factor (PAF), collagen, thromboxan 
A2 (TXA2) and epinephrine. Ristocetin induces 
platelet aggregation by mechanism involving von 
Willebrand factor and its glycoprotein Ib receptor. 
In our study we used TRAP-6 for platelet activa-
Figure 6. Effect of study solutions on platelet aggregation 
assessed by thrombin receptor activating peptide (TRAP); 
BL — baseline; PL — Plasmalyte®; VL — Volulyte®; 
GEL — Geloplasma®.
Figure 7. Effect of study solutions on platelet-depend-
ent clot strength; BL — baseline; PL — Plasmalyte®; 
VL — Volulyte®; GEL — Geloplasma®; MCE — maxi-
mum clot elasticity.
Discussion
Dilution due to aggressive fluid resuscitation 
leads to decreased concentration of clotting fac-
tors and number of platelets. It is interesting as to 
whether this affect is purely quantitative, or there 
are some qualitative effect as well. The present 
study evaluated the effect of three commonly used 
intravenous fluids on platelets in an in vitro set-
ting. Although 20 vol.% dilution with study fluids 
caused significant drop in platelet count, there was 
no effect on platelet aggregation, and all values 
for functional and standard tests (with exception 
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tion. It is known that increasing concentration of 
Ca+2 impairs platelet aggregation in vitro [18]. In 
the present study this was not an issue as we used 
balanced crystalloid and colloids with no extra 
calcium added.
In a prospective study in which Gelofusine® 
(4% succinylated gelatin) was infused into young 
volunteers, the authors reported a significant in-
crease in bleeding time, impairment of ristocetin-
induced platelet aggregation, what might have 
been related to gelatin-induced deficiency of von 
Willebrand factor [19]. Some authors emphasize 
a beneficial effect of gelatins as their antiaggrega-
tory properties might provide a degree of protection 
from thrombosis in trauma patients [20]. Platelets 
have been observed to be main contributors to 
increased coagulation after trauma [21]. Similarly 
HES-induced coagulopathy might counteract the ef-
fects of intra-operative activation of coagulation [22].
As far as primary hemostasis is concerned, 
it is important to distinguish between aggre-
gation and adhesion. None of in vitro tests of 
coagulation was able to measure impact of vas-
cular endothelium on hemostasis. ROTEM as 
a diagnostic measure using a whole blood sample, 
taking into account other physiologic parameters 
(e.g. temperature, ionized calcium, presence of 
anticoagulants), is the most accurate test for diag-
nosing actual coagulopathy. The endothelial com-
ponent of coagulation is missing in both ROTEM 
or MEA.
An important topic is the impact of synthetic 
colloids (used as a priming solution) on bleeding in 
cardiac surgery performed with cardiopulmonary 
bypass. Bleeding is common in cardiac surgery. 
Based on results of the present in vitro research, 
the use of succinylated gelatin and HES as a prim-
ing solution should be cautious [23].
Limitations of the study
First of all, only 20 vol.% blood dilution was 
made, what may be insufficient to observe co-
agulation abnormalities. Clinically relevant effects 
of synthetic plasma expanders on bleeding are 
present when large volumes (> 20 mL/kg) are 
infused or when patients present a priori with co-
agulopathy [20]. This study attempted to mitigate 
this drawback using sensitive functional testing, 
i.e. DMCE in ROTEM and MEA analysis. The 
study herein ran two assays simultaneously, one 
with platelet inhibitor and one without, to identify 
specific coagulopathy caused by platelet defect. 
The effect of the study solutions on platelet com-
ponent of clot strength as measured by ROTEM 
parameters showed decreased MCE for all three 
study solutions, which was more pronounced for 
HES and gelatin. Measuring platelet-dependent 
clot strength by elasticity, as opposed to clot am-
plitude, is sound because the relationship between 
clot amplitude and clot elasticity is nonlinear and 
clot elasticity, unlike clot amplitude, reflects the 
force of the blood clot resisting rotation within the 
device [24]. Moreover clot strength, as measured 
by clot amplitude, depends not only on platelets, 
but also on fibrinogen and factor XIII concentra-
tions, although the relative contribution of platelets 
is approximately 80% [21]. Based on clot elasticity, 
platelet contribution is 87–94% [25]. Secondly, 
the quantity of von Willebrand factor may impact 
clot stability and resulting bleeding time [19], 
postoperative blood loss [26], however in the 
present study its concentration was not measured. 
Thirdly, MEA was used for testing platelet func-
tion, whereas the most objective test of platelet 
function is LTA. Another limitation is the fact that 
observations are based on in vitro experiments 
what may differ from conditions caused by true fluid 
resuscitation, including recruitment of additional 
resources of the coagulation system, response to 
tissue and endothelial injuries, as well as changes 
in kinetics, volume of distribution or acid-base 
balance. Therefore in vivo studies deliver more 
physiological data. On the other hand, findings in 
healthy volunteers would also differ from those in 
actual massive bleeding. Finally, there was no con-
trol group for balanced solutions. It was however 
revealed that carrier solution had little impact on 
platelet aggregation and clot formation [15, 27]. 
Conclusions
The effect of balanced crystalloids and colloids 
on platelet aggregation is insignificant, even after 
20% volume substitution.
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